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Methods for the identification and selection of patients (cases) with severe or very severe pneumonia and
controls for the Pneumonia Etiology Research for Child Health (PERCH) project were needed. Issues
considered include eligibility criteria and sampling strategies, whether to enroll hospital or community
controls, whether to exclude controls with upper respiratory tract infection (URTI) or nonsevere pneumonia,
and matching criteria, among others. PERCH ultimately decided to enroll community controls and an
additional human immunodeficiency virus (HIV)–infected control group at high HIV-prevalence sites
matched on age and enrollment date of cases; controls with symptoms of URTI or nonsevere pneumonia will
not be excluded. Systematic sampling of cases (when necessary) and random sampling of controls will be
implemented. For each issue, we present the options that were considered, the advantages and disadvantages
of each, the rationale for the methods selected for PERCH, and remaining implications and limitations.
The Pneumonia Etiology Research for Child Health
(PERCH) study aims to be the largest study of the eti-
ology of severe pneumonia in children in.20 years [1].
Unlike many pneumonia etiology studies, PERCH
was designed as a case-control study, with controls
providing essential data for the interpretation and
extrapolation of findings from patients (cases). Spe-
cifically, controls will help improve interpretation of
test results from nasopharyngeal samples, determine the
specificity of certain diagnostic blood tests that are cali-
brated using normal values from the general population
(eg, Mycoplasma pneumoniae immunoglobulin M
serology), and identify risk factors (and estimate the
magnitude of association as an odds ratio) for severe
pneumonia and for etiologic-specific pneumonia.
Additionally, the use of controls allows us to estimate
population-attributable risks and compare communities
in which the study is done, and guides the interpretation
of any differences in the etiologic distribution of pneu-
monia cases between sites.
An essential component of PERCH is the case and
control selection process, which must be standardized
across the study sites located in 7 countries: Dhaka and
Matlab, Bangladesh; Basse, The Gambia; Kilifi, Kenya;
Bamako, Mali; Soweto, South Africa; Nakhon Phanom
and Sa Kaeo, Thailand; and Lusaka, Zambia. Epidemi-
ologic challenges addressed in the design of PERCH
included eligibility criteria for case and control
enrollment, matching criteria, the sampling strategy
for both cases and controls, where to identify controls,
and whether to enroll controls with upper respiratory
tract infection (URTI) or nonsevere pneumonia. The
methods chosen needed to (1) ensure study objectives
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could be met, (2) ensure adequate sample size, (3) minimize
selection bias, and (4) anticipate the need to control for con-
founding in analyses.
The PERCH Core Team presented options for each issue,
usually identifying 1 preferred option, to the Pneumonia
Methods Working Group (PMWG) [1] for consideration and
recommendation. The PERCH Core Team and the site inves-
tigators adapted the final recommendations of the PMWG to the
study’s protocol [2].
This manuscript summarizes decisions made by the PMWG
and PERCH Core Team about the principles of case and control
selection. It describes the case and control identification and
selection methods that were ultimately decided for PERCH,
and the options considered along the decision pathway, the
implications and tradeoffs for each, and rationale for the final
decisions.
METHODS
Case Identification and Selection
Case Eligibility Criteria
We will limit case enrollment to children hospitalized with
World Health Organization–defined severe or very severe
pneumonia [3]. Sites will enroll cases throughout the year to
obtain seasonal distribution of cases and throughout the week
and day, including weekends and evenings/nights, to enroll
cases representative of the distribution of disease severity.
Enrollment rates will be proportional to case detection rates,
meaning a greater number of cases will be enrolled during peak
hours and during peak seasons (Figure 1).
Defining the Reference Population and Catchment Area
Risk factors and circulating pathogens are expected to vary
within the study populations. To avoid bias, cases and controls
must be selected from the same reference population. We
therefore need to define the reference population from which
cases, detected at study hospitals, are drawn and select controls
from the same geographic area. We considered several factors
in defining the reference population. In settings with a single
referral hospital, cases may originate from great distances
because the hospital attracts severely ill children. Patients may
come from varied settings, such as urban and rural areas. In
large, densely populated cities with several hospitals and
highly mobile populations, it may be difficult to define the
areas from which cases come because hospital quality and cost
may take precedence over distance in determining the choice
of facility.
The catchment area is the study-defined geographic area
where eligible study participants (both cases and controls;
a subset of the reference population) must live. The catchment
area will be defined using residence of cases obtained from
hospital logs the previous year. Sites will define the catchment
area based on where most cases came from the previous year to
avoid having to enroll controls over a too expansive an area. This
also has the benefit of not overrepresenting controls from very
distant areas that rarely use the study hospital, and of not
overrepresenting cases that are not representative of the study
site population (ie, from great distances or only visiting the
study area). However, excluding the farthest cases may risk
excluding the most severe cases resulting from delay in pre-
senting for medical care due to travelling farther distances when
seeking hospital care.
Need to Limit the Number of Cases Enrolled
Power calculations suggested that approximately 6300 cases
(and 7000 controls) would be sufficient to evaluate all primary
and secondary objectives of PERCH. However, projections from
the 7 PERCH sites indicate that nearly twice as many eligible
cases (approximately 12 500) might be expected to present at
the enrollment hospitals over the course of 2 years. Therefore,
several options were considered to limit the number of cases
enrolled (see Supplementary Table 1). Options 1–3 were
rejected because they potentially biased the representativeness
of the study population. Option 4 (testing only a proportion of
specimens) would reduce costs, but the effort to enroll all cases
at very large hospitals would be burdensome. However, from
an ethical standpoint it would not be acceptable to collect
specimens that are not tested or enroll cases that would not
be included in analyses. Although case sampling (option 5)
introduced complexity into the study design, it did not suffer
from the previously noted disadvantages and was the preferred
option. Thus, a system for selecting the cases to be enrolled
among all those eligible was needed.
Case Sampling
Any form of sampling increases study complexity and poten-
tially introduces bias, but some forms more so than others. We
considered random, systematic (eg, enroll every other case or
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Figure 1. An illustration of case and control sampling proportional to
the case detection rates. A small time lag is anticipated for controls
frequency-matched to the month of enrollment of cases, due to the
expected interval from observed cases to the communication of this
target number to the field workers who recruit controls.
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every other day), convenience (eg, enrollment only between 9 AM
and 5 PM on weekdays), and quota (eg, stop when prespecified
sample size for that week or month is reached) sampling
methods. Whereas random selection was thought to be
too logistically complicated to realistically implement, the
remaining methods with preselected days or times for enroll-
ment were thought to be subject to selection bias resulting
from families bringing their children during ‘‘study’’ times.
The best option was determined to be systematic sampling
with rotating enrollment (ie, alternating which days or hours
to enroll).
A benefit of sampling is that it affords an opportunity to
control the enrollment ratio of severe to very severe pneumonia
cases, which are expected to be fewer. Because PERCH’s focus is
on identifying pathogens responsible for fatal pneumonia, we
sought to increase enrollment of very severe cases. As a result,
systematic sampling may be applied only to (or more fre-
quently to) the severe cases; at many sites, all very severe cases
will be invited to participate. This is a form of selection bias,
albeit one we chose and can control for in the analysis. To
optimize analyses stratified by severity, we will aim to balance
the ratio. Some sites (Kenya and The Gambia) with projected
excess cases will enroll all cases during the first year and sample
only during the second year, if necessary. At least 1 site
(Thailand) anticipates enrolling all eligible cases and will not
apply any sampling criteria.
To minimize selection bias, a dedicated study team (rather
than regular hospital staff) will manage the detection, selection,
and enrollment of cases at most sites. Key data collected on
all admissions, such as age, residence in catchment area,
and admission diagnosis from existing hospital sources (eg,
admission registers), will help assess the representativeness of
the enrolled cases (Figure 2). Children who are screened will be
compared with those not screened, and children who are
enrolled will be compared with those not enrolled, to assess
the representativeness of the PERCH participants. We will
identify those who would potentially be eligible but were not
screened for enrollment using a set of predefined diagnoses
(eg, pneumonia, acute lower respiratory infection, bron-
chiolitis) on admission registers.
Figure 2. An illustration of the patient flowchart. Abbreviations: OPD, outpatient department; ER, emergency room; ARI, acute respiratory infection;
PERCH, Pneumonia Etiology Research for Child Health Study.
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Case Representativeness
The previously noted methodological decisions will result in
many cases of severe pneumonia that will not be captured by
PERCH. An inherent limitation of the focus on hospitalized
cases is that we will miss cases who never come to hospital or
who die at presentation before they can be enrolled. At the
Kenya site, approximately two-thirds of children who die do so
in the community [4], and only half of hospitalized children
with severe or very severe pneumonia who died during their
hospital stay participated in an etiology study [5]; thus, missed
cases may represent those of greatest interest. This is an inherent
paradox in hospital-based pneumonia etiology studies that
must be accepted; however, to mitigate the consequences, we
aim to collect postmortem specimens at 6 sites that may
provide insights into the etiology of those who die at or near
the time of presentation to hospital [6]. We will also miss the
cases who seek care at nonstudy facilities or are not selected
for enrollment because of sampling strategies. Although we
cannot control the former situation, we will try to minimize
the bias in the latter through sampling and analytic methods.
The diversity of sites and the large sample size of PERCH will
help ensure that we enroll a variety of cases, for which, using
subgroup analyses, results can be generalized within these
communities and to other similar communities.
Control Identification and Selection
Community Versus Hospital Controls
We aim to enroll controls that are representative of the pop-
ulation from which cases are drawn. Limited funds restricted us
to only 1 control group, either from the community or from the
study hospital. These 2 alternative groups have advantages and
disadvantages in enabling us to understand the roles of risk
factors and detection biases (Supplementary Table 2). Selecting
hospital controls would best minimize selection bias due to
access to care because both cases and controls have taken
the same route to care. However, we were concerned that an
insufficient number of eligible controls would be found at the
hospital. Another concern was that they would be distorted by
pneumonia-causing pathogens that can cause other inpatient
syndromes such as sepsis, febrile convulsions, and diarrheal
disease. They also would likely overrepresent the community
prevalence of risk factors needed to calculate population-
attributable risks and complicate the interpretation of findings
from nasopharyngeal specimen testing.
Therefore, we decided that a community control group would
best meet the analytic objectives of the study. They may be more
representative of the catchment population than hospitalized
children who might have underlying conditions (eg, malnutri-
tion, human immunodeficiency virus [HIV] infection) that are
not representative of the general population and that we would
want to evaluate as risk factors for pneumonia. They would also
not be skewed with respect to circulating pneumonia-causing
pathogens, which hospital controls may have been.
Despite their advantages, using community controls does
have some disadvantages. There are greater logistical challenges,
such as identifying and locating eligible children who are
scattered throughout a relatively large geographic area,
selecting among them in an unbiased way, and the need for
mobile, trained teams to collect their data. However, 3 sites
already have extensive, successful experience enrolling controls
from the community. In The Gambia, community awareness
raised through radio programs helped successfully enroll controls
in similar proportions to cases (S. Howie, written personal
communication, 2009). In Dhaka, Bangladesh, community
control enrollment was .95% in previous studies [7–9]. Mali
has extensive experience enrolling healthy community controls
that includes in-field random selection techniques and matching
up to 3 controls per case by age, sex, neighborhood, and case-
enrollment date [10].
There may also be residual uncertainty about differences in
healthcare-seeking behavior and other health-related behaviors
between community controls and cases. Healthcare-seeking
tendencies may confound both etiology and risk-factor analy-
ses, because cases who seek care may differ from cases who do
not seek care regarding characteristics associated with etiology.
Such characteristics include vaccination against pneumonia-
causing pathogens, residence (because circulating pathogens
differ by community), socioeconomic status and ability to
afford care, access to early effective treatment that will shift
etiology to antibiotic-resistant organisms and viruses, nutri-
tion, crowding, and HIV status, among other risk factors. We
are collecting information on all these factors in cases and
controls, to control for them in the analysis.
A greater challenge with community controls might be the
collection of specimens, particularly blood samples. Collecting
blood is often a sensitive issue, the more so among well children.
Taking the time to inform the community and each control
child’s parents and explaining carefully what we are doing and
why is likely to overcome most of the resistance to blood sam-
pling. As a potential benefit for participation, many sites will
provide blood test results (HIV, thalassemia, sickle cell disease,
or anemia) to the parents, and refer them for care if results are
positive.
Community Control Selection Strategy
Community controls will be randomly selected from lists of
previously enumerated children residing in Demographic Sur-
veillance System areas (Kenya, The Gambia, Bangladesh), where
birth registries exist (South Africa), or from lists of households
in areas with existing registries of households (Thailand). In
the remaining 2 sites, they will be selected using the Expanded
Program on Immunization cluster-sampling method [11]. Other
sampling methods we considered included creating geographic
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‘‘quotas’’ of controls that ensured equal representativeness of
all areas, and selecting controls from among children presenting
to community health centers for routine visits. However, these
methods were thought to bias controls toward those with
good access to care, those who are unwell, or children of
vaccine-eligible age.
To minimize bias in the selection of controls, field workers
will revisit selected households #3 times if eligible children are
not at home on the first visit. When possible, to optimize
recruitment of the random sample, field workers will visit the
household in the early morning or evening hours or make
appointments by partnering with village health volunteers.
Widespread community dissemination of information about
the study may also help reduce refusals.
Matching and Number of Controls per Case
Because in most sites the incidence of pneumonia is highly
seasonal and the pathogens that cause pneumonia are also
seasonal, we debated whether to match controls to the dates of
enrollment of cases or to recruit controls at a constant rate
throughout the year. The advantage of matching would be to
increase the power of season-stratified analyses, whereas constant
recruitment would assure adequate measurement of background
prevalence of risk factors and etiology in all seasons. To achieve
both benefits, we decided on a combination of the 2 approaches,
resulting in slightly .1 control enrolled per case. PERCH sites
will recruit a minimum of 25 controls per month, and in
months with .25 cases enrolled, sites will enroll additional
controls for a 1:1 ratio for that month (Figure 1). Controls will
also be frequency matched on age to the cases based on previous
years’ data and adjusted if needed in the following groups:
28 days to,6 months, 6 to,12months, 12 to,24months, and
24–59 months.
Healthy Versus Sick Controls
We considered whether children with nonsevere pneumonia or
URTI characterized by coryza, cough, sneezing, and sore throat
should be excluded or enrolled and analyzed as separate control
groups. Our understanding of the pathogenesis of pneumonia
suggests that most pathogens that infect the lung begin by first
infecting the upper respiratory tract and that many of these
infections cause URTI symptoms. The concern, therefore, is that
URTIs and nonsevere pneumonia could be the early stages of
severe pneumonia. However, because the control group should
represent the population from which the cases are drawn,
because not all URTIs are on the causal pathway to pneumonia,
and because some pathogens cause both URTIs and severe
pneumonia, an unbiased control population should include
children in any state of health, including those with URTI or
nonsevere pneumonia, provided that they do not have case-
defining severe or very severe pneumonia at the time of enroll-
ment. This decision has 3 significant advantages: (1) It permits
an unbiased estimate of the prevalence of exposure variables in
the community; (2) it prevents a form of selection bias that
could overestimate the role of viral pathogens as the cause of
severe pneumonia (otherwise we would have to apply the same
rule of excluding URTI patients to cases); (3) it broadens the
scope for exploratory analyses regarding the spectrum of illness;
and (4) it estimates the prevalence of URTIs and nonsevere
pneumonia in the community.
For PERCH, we will exclude as controls children with case-
defining severe or very severe pneumonia [3] but not those
with symptoms of URTI or nonsevere pneumonia. Including
controls with respiratory illness will give us an opportunity to
explore the role of nasopharyngeal infection in the pathogen-
esis of pneumonia through subgroup analyses. Exploratory
questions that can be examined with a URTI subgroup include:
(1) Is the URTI in the causal pathway (a gradient of infection)?
(2) Which pathogens commonly cause URTI but rarely pneu-
monia? and (3) Is a virus a facilitating cofactor in pneumonia
caused by a bacterial pathogen? If a sufficient number of con-
trols with nonsevere pneumonia are enrolled, we can test the
relationship between etiology and intermediary stages on the
causal pathway to severe pneumonia. Specifically, we can assess
whether the etiologic spectrum of nonsevere pneumonia is
more similar to URTI, severe pneumonia, or somewhere in
between. Although defining distinct respiratory syndromes that
can occur along the continuum of respiratory infections will be
challenging because symptoms of each syndrome will overlap,
use of standardized definitions and training will help limit
misclassification.
HIV-Infected Controls
Because we expect the etiologic spectrum of pneumonia to differ
markedly by HIV status [12, 13], stratifying etiologic analyses
by HIV status is necessary. We anticipate 25%–50% of cases to
be HIV-infected at sites with high HIV prevalence (ie, Zambia
and South Africa). However, because the community preva-
lence of HIV infection will likely be ,5% even in sites of high
HIV prevalence, an additional HIV-infected control group is
needed to achieve sufficient numbers for HIV-stratified etio-
logic analyses. A separate HIV control group is not needed for
risk factor analyses.
We considered selecting HIV controls from admitted patients
at the hospital (see Supplementary Table 3), but the 2–3-day
lag time to diagnose HIV infection among inpatients may alter
the naso-oropharyngeal flora with nosocomial pathogens. In
addition, HIV-infected infants admitted with nonpneumonia
diagnoses have been difficult to find in South Africa because of
improved prevention of mother-to-child transmission and
lower prevalence of HIV infection among newborns. Therefore,
controls will be selected from HIV treatment clinics serving the
hospital catchment population.
HIV-infected controls will be enrolled in a 1:1 ratio to
HIV-infected cases, frequency-matched by age and month of
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enrollment; there will be no monthly minimum. Enrollment
will be stratified on the duration of antiretroviral treatment
(,3 months vs $3 months) to adjust for the level of immu-
nosuppression that can influence the presence of pathogens
in the naso-oropharynx. Eligibility criteria are the same as for
community controls, plus the HIV-infected controls must be
confirmed HIV infected and should not have been admitted to
a hospital with an acute illness within the preceding 30 days.
The latter criterion was added because acute illness can alter the
CD4 count, which we will adjust for as an indicator of stage of
HIV disease severity.
Multiple Enrollments in PERCH
We decided that a case may be reenrolled as a case if the patient
is admitted .30 days after the date of hospital discharge from
the previous case episode. This is to ensure that the same
pneumonia episode is not enrolled twice.
If a control develops severe or very severe pneumonia within
48 hours of their control enrollment date, this control enroll-
ment will be excluded, but the child would be eligible to be
a case. This is because any URTI that the child had at the time
of control enrollment might have been the early stage of the
pneumonia and is considered the same episode as case-defining
pneumonia.
To be consistent in the treatment of cases and controls, a child
who was previously a case may be enrolled as a control if the
control enrollment date is .30 days after the date of hospital
discharge from the previous case episode. There is no time
period of exclusion between control enrollments, and a com-
munity control may be enrolled again as a control if reselected
through the random selection process. However, HIV-infected
controls may be selected only once because the smaller pool of
eligible children is likely to result in many repeat invitations to
participate in some age groups.
CONCLUSIONS
Despite their limitations, case-control studies of pneumonia
etiology can provide valuable information on the likely causes of
severe and fatal pneumonia in children. Although more expen-
sive, complicated, and time-consuming than a study of hospi-
talized patients only, the case-control study provides valuable
information that is often missing frommore-limited studies. For
example, a control group clarifies the usefulness and interpre-
tation of some results from upper respiratory specimens, which
are otherwise complicated and potentially misleading [5, 13–15].
Pneumonia etiology information is most helpful when it is
collected from representative cases and controls. However,
hospital-based studies of cases and selection of representative
controls from the population are complicated and potentially
open to biases that can alter the conclusions. The PERCH
project has gone to great efforts to attenuate these limitations.
By employing sampling strategies to reduce bias among cases
and controls, taking steps to minimize participant refusal,
gathering data on potential confounders to use in the analysis,
and enrolling controls along the continuum of respiratory
illness, PERCH aims to address concerns about bias by min-
imizing it, assessing where it may occur, and mitigating it
by collection of overlapping information and specimens. The
description of these methods and their rationale in this man-
uscript is designed to help with the interpretation of PERCH
results when they are available and with the design of other
pneumonia etiology research studies.
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